CSL Limited
CSL
Classifica tra le azioni
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Prezzo delle azioni
$138.43
Capitalizzazione di mercato
$66.43B
Variazione (1 giorno)
-0.14%
Variazione (1 anno)
-3.24%
Paese
AU
Scambia CSL Limited (CSL)
Categoria
Healthcare
Ricavi di CSL Limited (CSL)
Ricavi nel Jun 2026 TTM: $15.74B
Secondo gli ultimi rapporti finanziari di CSL Limited, i ricavi attuali dell'azienda (TTM) sono pari a $15.74B. Nel 2024, l'azienda ha registrato ricavi di $14.69B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $13.17B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per CSL Limited da 2000 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $15.74B | 2.04% |
| 2025 | $15.43B | 5.04% |
| 2024 | $14.69B | 11.51% |
| 2023 | $13.17B | 25.55% |
| 2022 | $10.49B | 1.56% |
| 2021 | $10.33B | 9.84% |
| 2020 | $9.41B | 13.08% |
| 2019 | $8.32B | 11.54% |
| 2018 | $7.46B | 6.28% |
| 2017 | $7.02B | 15.81% |
| 2016 | $6.06B | 11.00% |
| 2015 | $5.46B | 8.91% |
| 2014 | $5.01B | 10.79% |
| 2013 | $4.52B | -2.44% |
| 2012 | $4.64B | -3.37% |
| 2011 | $4.80B | 49.63% |
| 2010 | $3.21B | 6.25% |
| 2009 | $3.02B | -7.53% |
| 2008 | $3.26B | 42.87% |
| 2007 | $2.28B | 45.52% |
| 2006 | $1.57B | -1.58% |
| 2005 | $1.60B | 98.59% |
| 2004 | $803.28M | 36.45% |
| 2003 | $588.71M | 38.88% |
| 2002 | $423.90M | -2.21% |
| 2001 | $433.49M | 0.00% |
| 2000 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | -19.82% |
US
|
|
| $2.23B | -85.85% |
US
|
|
| - | - |
CH
|
|
| $6.02B | -61.76% |
NL
|
|
| $10.11B | -35.78% |
BE
|
